https://kerna.medium.com/inside-big-pharma-what-16-giants-are-betting-on-next-8286456ff72e2025-06-01monthly0.7 https://kerna.medium.com2026-06-02weekly1.0 https://kerna.medium.com/about2026-06-02weekly1.0 https://kerna.medium.com/trillions-within-us-the-microbiome-first-unicorns-85aed17a50822023-04-13monthly0.7 https://kerna.medium.com/from-kernel-to-rna-the-story-behind-kerna-ventures-b4ac914b9f8d2024-02-15monthly0.7 https://kerna.medium.com/generative-ai-hype-beyond-c5ec9eacb1d52023-05-30monthly0.7 https://kerna.medium.com/gene-editing-now-fda-blessed-620a070976052023-12-18monthly0.7 https://kerna.medium.com/pioneers-of-promise-top-40-in-gene-delivery-9ccebda66d6f2024-05-01monthly1.0 https://kerna.medium.com/the-in-vivo-car-t-race-02342724ad882025-03-01monthly0.7 https://kerna.medium.com/the-biggest-losers-obesity-therapeutics-landscape-1a3c114356a52025-09-02monthly0.7 https://kerna.medium.com/blood-brain-barrier-hitchhikers-the-future-of-cns-therapeutics-8912ab72fb152025-11-03monthly1.0 https://kerna.medium.com/in-vivo-car-t-and-b-cell-depletion-where-to-next-e7004ee72df32026-06-02daily0.7